Cite
HARVARD Citation
Hall, E. et al. (2021). Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. Journal for immunotherapy of cancer. 9 (1), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Hall, E. et al. (2021). Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. Journal for immunotherapy of cancer. 9 (1), p. . [Online].